Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 41Breast Neoplasms 40Lung Neoplasms 25Carcinoma, Non-Small-Cell Lung 20Colorectal Neoplasms 19Uterine Cervical Neoplasms 13Prostatic Neoplasms 13Head and Neck Neoplasms 11Carcinoma, Hepatocellular 11Pancreatic Neoplasms 10Melanoma 10Ovarian Neoplasms 9Neoplastic Cells, Circulating 7Myelodysplastic Syndromes 7Glioma 7Esophageal Neoplasms 7Endometrial Neoplasms 7Brain Neoplasms 7Sarcoma 6Multiple Myeloma 6Gastrointestinal Neoplasms 6Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Disease 5Colonic Neoplasms 5Uveal Melanoma 4Skin Neoplasms 4Neoplasm, Residual 4

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High Grade Neuroendocrine Neoplasms × Blood Specimen Collection × 1 year × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡